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Background:  Although anthracycline (AC) exposure predisposes one to cardiotoxicity, early subclinical markers are largely unavailable. In a recent 
animal model, we identified a cardiovascular magnetic resonance (CMR) method for measuring gadolinium signal intensity (Gd-SI) changes that 
identified early histopathologic evidence of myocellular injury after AC therapy that subsequently forecasted a decrement in left ventricular ejection 
fraction. The purpose of this study was to determine in patients if Gd-SI changed after AC versus non-AC therapy.
Methods:  As part of a National Cancer Institute funded cohort study, 33 patients aged 49 ± 13 years (75% women) with breast cancer, lymphoma 
or leukemia received AC (n=25) or herceptin, cytoxan or taxol (n=8). Demographic and historical cardiovascular data was recorded. Gradient echo 
inversion recovery CMR scans (TR/TE/TI = 821.6/3.3/260 ms) were acquired before start of therapy and again 1, 3, and 6 months thereafter. Gd-SI 
was determined in 3 short axis views (base, middle, apex) 20 mins after Gd was given (0.1 mmole/kg gadobenate). A longitudinal mixed model was 
to fit the data treating patients as a random effect.
Results:  Variables were similar in patient groups including age, gender, cancer type, and history of hypertension, diabetes, hyperlipidemia and 
coronary artery disease (p=NS for all). Left ventricular ejection fraction in AC and non-AC groups were similar at baseline (58.6 ± 8.0 and 55.9 ± 
4.8, respectively) without decrements at 6 months (p=NS). Mean (+ std error) Gd-SI in non-AC patients remained unchanged from baseline to 6 
months (13.8 ± 4.1 to 14.3 ± 4.3; p=NS) while mean Gd-SI in AC patients increased from 12.2 ± 1.7 to 16.9 ± 3.2, (p<0.0001). We tested for time 
interaction by AC use and found it significant suggesting that the rate of increase was higher in AC patients than in non-AC patients (p<0.0001).
Conclusions:  CMR gadolinium signal intensity (Gd-SI) increases in patients with breast cancer or hematologic malignancy after anthracycline 
chemotherapy (AC) but not necessarily non-AC therapy. Changes in Gd-SI in patients may serve as an early subclinical marker of AC cardiotoxicity 
prior to changes in left ventricular ejection fraction.
